PTC Therapeutics | PTCT - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Cytokinetics USD 17.76M 15.82M 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Novartis USD 10.07B 184M 2026-03
Pfizer USD 12.28B 8.74B 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03
Xencor USD 21M 22.61M 2025-09